<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="120992">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01867671</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT ITN050AD</org_study_id>
    <nct_id>NCT01867671</nct_id>
  </id_info>
  <brief_title>Peanut Oral Immunotherapy in Children</brief_title>
  <acronym>IMPACT</acronym>
  <official_title>Oral Immunotherapy for Induction of Tolerance and Desensitization in Peanut-Allergic Children (ITN050AD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immune Tolerance Network (ITN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multi-center study comparing peanut
      oral immunotherapy (OIT) to placebo. Eligible participants with peanut allergy will be
      randomly assigned to receive either peanut OIT or placebo for 134 weeks followed by peanut
      avoidance for 26 weeks.

      An initial oral food challenge (OFC) to 1 g of peanut flour (500 mg peanut protein) will be
      conducted. Participants must have a clinical reaction during this OFC to initiate study
      dosing. After the initial OFC, the study design includes four phases:

        -  Initial dose escalation (1 day): Peanut or placebo dosing will be given incrementally
           and increase every 20 minutes until a dose of 12 mg peanut flour (6 mg peanut protein)
           or placebo flour is given.

        -  Build-up (30 weeks): Initial observed dose administration of highest tolerated dose,
           followed by daily OIT at home with return visit every 2 weeks for dose escalation.

        -  Maintenance (104 weeks):The participant will continue on daily OIT with return visits
           every 13 weeks. At the end of this phase the participant will undergo a blinded OFC to
           10 g peanut flour (5 g peanut protein).

        -  Avoidance (26 weeks): In this final phase participants will be seen every 13 weeks. At
           the completion of this phase participants will have a final blinded OFC to 10g peanut
           flour (5 g peanut protein).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of Desensitized Subjects</measure>
    <time_frame>week 134</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants who pass an oral food challenge (OFC) to 10 g of peanut flour (5 g of peanut protein) at this time without significant symptoms will be considered desensitized to peanut. Failure will be defined as either unable to undergo the final food challenge or inability to tolerate the maximum dose because of significant symptoms such as hives, wheezing, vomiting, or laryngeal edema.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance Endpoint</measure>
    <time_frame>week 160</time_frame>
    <safety_issue>No</safety_issue>
    <description>The proportion of participants who pass the OFC to 10 g peanut flour (5 g peanut protein).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient Desensitization</measure>
    <time_frame>week 134 to week 160</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in proportion of participants who pass the OFC to 10 g peanut flour (5 g peanut protein)at week 134 and week 160.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Highest Tolerated Cumulative Dose</measure>
    <time_frame>week 160</time_frame>
    <safety_issue>No</safety_issue>
    <description>The highest tolerated cumulative dose of peanut protein during the OFCs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of all adverse events</measure>
    <time_frame>week 160</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Withdrawal from OIT or Placebo</measure>
    <time_frame>week 160</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Peanut Hypersensitivity</condition>
  <arm_group>
    <arm_group_label>Peanut Oral Immune Therapy (OIT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peanut OIT for 134 weeks followed by peanut avoidance for 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peanut Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Peanut placebo for 134 weeks followed by peanut avoidance for 26 weeks. The placebo extract will be derived from oat flour source material.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peanut Oral Immunotherapy - Liquid Extract</intervention_name>
    <description>Used during initial dose escalation for doses 0.1 to 0.8 mg.</description>
    <arm_group_label>Peanut Oral Immune Therapy (OIT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo for Peanut Oral Immunotherapy - Liquid Extract form</intervention_name>
    <description>Similar in appearance, texture, and taste to peanut liquid extract.</description>
    <arm_group_label>Peanut Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peanut Oral Immunotherapy - Peanut Flour</intervention_name>
    <description>This will be used for the remainder of dose escalation, build-up, and maintenance.</description>
    <arm_group_label>Peanut Oral Immune Therapy (OIT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo for Peanut Oral Immunotherapy - Peanut Flour</intervention_name>
    <description>Similar in appearance, texture, and taste to peanut flour.</description>
    <arm_group_label>Peanut Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical history of peanut allergy or avoidance of peanut without ever having eaten
             peanut.

          -  Serum immunoglobulin E(IgE) to peanut of &gt; 5 kUA/L determined by UniCAP, an in-vitro
             test system for diagnosis and monitoring of allergy and inflammation

          -  Wheal â‰¥ 3mm on skin prick test to peanut extract compared to a negative control.

          -  A clinical reaction at or below ingestion of 1 g peanut flour (500 mg peanut protein)
             during screening OFC

          -  Written informed consent from parent/guardian

        Exclusion Criteria:

          -  History of severe anaphylaxis with hypotension to peanut

          -  Documented clinical history of allergy to oat

          -  Suspected allergy to oat and a wheal greater than or equal to 7mm on skin prick test
             to oat extract compared to a negative control

          -  Chronic disease other than asthma, atopic dermatitis, rhinitis requiring therapy;
             e.g., heart disease or diabetes

          -  Active eosinophilic gastrointestinal disease in the past 2 years

          -  Participation in any interventional study for the treatment of food allergy in the 6
             months prior to visit -1

          -  Inhalant allergen immunotherapy that has not yet reached maintenance dosing

          -  Severe asthma, as indicated by repeated hospitalizations or hospital emergency
             department visits

          -  Moderate asthma defined according to National Asthma Education and Prevention Program
             Expert

          -  Panel that requires more than fluticasone 440 mcg or its equivalent daily for
             adequate control

          -  Inability to discontinue antihistamines for skin testing, OFC and the initial dose
             escalation

          -  Use of omalizumab or other non-traditional forms of allergen immunotherapy (e.g.,
             oral or sublingual) in the 12 months prior to visit -1

          -  Any systemic therapy which in the judgment of the investigator could be
             immunomodulatory (e.g. rituximab) in the 12 months prior to visit -1, Systemic
             corticosteroid therapy of up to a total of three weeks is allowed

          -  Use of any investigational drug in 90 days prior to visit -1

          -  Plan to use any investigational drug during the study period

          -  The presence of any medical condition that the investigator deems incompatible with
             participation in the trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>48 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wesley Burks, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UNC Chapel-Hill</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stacie M. Jones, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univeristy of Arkansas for Medical Sciences: Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Hiegel</last_name>
      <phone>501-364-3755</phone>
      <email>hiegelannem@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Stacie Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kyrsten Spann</last_name>
      <phone>650-724-0293</phone>
      <email>knspann@comcast.net</email>
    </contact>
    <investigator>
      <last_name>Kari Nadeau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rachel Brewer</last_name>
      <phone>410-502-1711</phone>
      <email>rbrewer3@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Wood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessica Gau</last_name>
      <phone>212-241-7637</phone>
      <email>jessica.gau@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Hugh Sampson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC Chapel-Hill</name>
      <address>
        <city>Chapel-Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pam Steele, MD</last_name>
      <phone>919-962-4416</phone>
      <email>phsteele@email.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Wesley Burks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.niaid.nih.gov/</url>
    <description>National Institute of Allergy and Infectious Diseases (NIAID)</description>
  </link>
  <link>
    <url>http://www.immunetolerance.org</url>
    <description>Immune Tolerance Network</description>
  </link>
  <link>
    <url>http://www.impactstudy.org</url>
    <description>Study Webpage</description>
  </link>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 6, 2013</lastchanged_date>
  <firstreceived_date>May 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergy, Peanut</keyword>
  <keyword>Peanut allergy</keyword>
  <keyword>Hypersensitivity</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Desensitization, Immunologic</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Peanut Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
